Share Price and Basic Stock Data
Last Updated: December 12, 2025, 6:55 pm
| PEG Ratio | -11.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vaxtex Cotfab Ltd has undergone a tumultuous journey in recent years, particularly evident in its revenue trajectory. The company reported a sharp decline in sales, plummeting from ₹75.62 Cr in March 2023 to just ₹5.25 Cr in March 2025. This staggering drop raises eyebrows, particularly given the firm had previously shown promise, achieving ₹61.91 Cr in sales in March 2022. The last few quarters have seen sales figures dwindle significantly, with a mere ₹4.10 Cr reported in September 2023. Such a drastic reduction indicates potential operational challenges or shifts in market demand that investors should closely monitor. A key concern is the ongoing trend of negative revenue in the upcoming quarters, which could signal deeper issues within the company’s business model or market positioning.
Profitability and Efficiency Metrics
Profitability metrics for Vaxtex Cotfab reveal a stark contrast between previous performance and the current state. The company’s operating profit margin (OPM) stood at a concerning -9.52% in March 2025, a significant decline from the 4.86% recorded in March 2022. This trend is mirrored in the net profit figures, which saw a steep drop into the red, marking a net loss of ₹8.83 Cr in March 2024, followed by a modest recovery to ₹0.88 Cr in March 2025. Furthermore, the return on equity (ROE) remains relatively low at 4.74%, indicating that shareholders may not be receiving adequate returns on their investments. The company’s cash conversion cycle has ballooned to an alarming 971.94 days, which suggests inefficiencies in managing inventory and receivables, posing significant operational risks that could further strain profitability.
Balance Sheet Strength and Financial Ratios
Vaxtex Cotfab’s balance sheet reveals a mixed picture of financial strength and vulnerabilities. The company reported total borrowings of ₹10.92 Cr, which, while manageable, raises concerns given the negative reserves of ₹-1.06 Cr. This negative equity position could hinder future financing options and investor confidence. The interest coverage ratio, standing at 5.58 times, indicates that the company can comfortably cover its interest obligations, yet this comfort may be short-lived if revenues do not stabilize. The price-to-book value (P/BV) ratio of 0.65x suggests that the stock may be undervalued, but this could also reflect the market’s skepticism regarding the company’s ability to recover from its current challenges. Overall, while the balance sheet has some strengths, significant risks linger, especially in terms of liquidity and solvency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Vaxtex Cotfab Ltd illustrates a growing reliance on public shareholders, with promoter ownership declining to 16.47% as of March 2025, down from 36.28% in December 2022. This shift could indicate a lack of confidence from promoters, which may raise red flags for potential investors. The absence of foreign institutional investors (FIIs) and the significant public stake of 83.53% indicate that retail investors are bearing the brunt of the stock’s volatility. The number of shareholders has also increased, reaching 41,499, suggesting a growing interest or perhaps a speculative approach among retail investors. However, the lack of institutional backing could limit the stock’s upward momentum, making it susceptible to larger market swings and investor sentiment.
Outlook, Risks, and Final Insight
The outlook for Vaxtex Cotfab Ltd is clouded by a combination of operational challenges and market dynamics. The declining revenue trend and negative profitability raise substantial risks for investors. If the company cannot reverse its sales trajectory and improve operational efficiencies, it could face severe liquidity issues, especially with a cash conversion cycle exceeding 971 days. Additionally, the shifting shareholding pattern and lack of institutional support could further affect market perception. However, if Vaxtex can identify and address its core issues, there remains a potential for recovery, especially given its low P/BV ratio, which might attract value-focused investors. Ultimately, prospective investors should weigh the risks of ongoing losses against the potential for a turnaround, keeping a close eye on quarterly performance and management’s strategic direction.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 108 Cr. | 28.0 | 796/25.8 | 1.05 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 1,602 Cr. | 159 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 47.2 Cr. | 3.70 | 8.65/3.55 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,680.30 Cr | 220.53 | 451.12 | 219.27 | 0.25% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.33 | 18.33 | 11.39 | 16.57 | 10.84 | 4.10 | 2.08 | -0.40 | 0.00 | 0.00 | 0.00 | 5.25 | 0.00 |
| Expenses | 28.86 | 17.91 | 12.82 | 16.43 | 10.30 | 3.93 | 10.72 | 0.82 | -0.09 | 0.11 | 0.37 | 5.34 | 0.21 |
| Operating Profit | 0.47 | 0.42 | -1.43 | 0.14 | 0.54 | 0.17 | -8.64 | -1.22 | 0.09 | -0.11 | -0.37 | -0.09 | -0.21 |
| OPM % | 1.60% | 2.29% | -12.55% | 0.84% | 4.98% | 4.15% | -415.38% | -1.71% | |||||
| Other Income | 0.64 | 0.11 | 1.57 | 0.16 | 0.05 | 0.01 | 0.02 | 0.44 | 0.02 | 0.03 | 0.01 | 1.06 | 0.46 |
| Interest | 0.28 | 0.36 | -0.02 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.06 | 0.02 |
| Depreciation | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.00 | 0.00 | 0.01 | 0.01 | 0.06 | 0.01 | 0.01 |
| Profit before tax | 0.76 | 0.10 | 0.09 | 0.23 | 0.50 | 0.09 | -8.63 | -0.79 | 0.08 | -0.11 | -0.44 | 0.90 | 0.22 |
| Tax % | 0.00% | 0.00% | 0.00% | 13.04% | 26.00% | 22.22% | 0.00% | -18.99% | 0.00% | 0.00% | -11.36% | -47.78% | 0.00% |
| Net Profit | 0.77 | 0.10 | 0.09 | 0.21 | 0.37 | 0.07 | -8.63 | -0.65 | 0.08 | -0.12 | -0.39 | 1.32 | 0.22 |
| EPS in Rs | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | -0.47 | -0.04 | 0.00 | -0.01 | -0.02 | 0.07 | 0.01 |
Last Updated: August 20, 2025, 1:30 am
Below is a detailed analysis of the quarterly data for Vaxtex Cotfab Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.25 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 5.25 Cr..
- For Expenses, as of Jun 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.34 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 5.13 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Mar 2025) to -0.21 Cr., marking a decrease of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -1.71% (Mar 2025) to 0.00%, marking an increase of 1.71%.
- For Other Income, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.60 Cr..
- For Interest, as of Jun 2025, the value is 0.02 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.22 Cr.. The value appears to be declining and may need further review. It has decreased from 0.90 Cr. (Mar 2025) to 0.22 Cr., marking a decrease of 0.68 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -47.78% (Mar 2025) to 0.00%, marking an increase of 47.78%.
- For Net Profit, as of Jun 2025, the value is 0.22 Cr.. The value appears to be declining and may need further review. It has decreased from 1.32 Cr. (Mar 2025) to 0.22 Cr., marking a decrease of 1.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.07 (Mar 2025) to 0.01, marking a decrease of 0.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.63 | 4.43 | 18.45 | 21.97 | 27.76 | 26.15 | 61.91 | 75.62 | 16.62 | 5.25 | 7.54 |
| Expenses | 0.00 | 0.01 | 0.65 | 4.41 | 18.08 | 21.03 | 26.39 | 24.71 | 58.90 | 75.77 | 23.02 | 5.75 | 8.32 |
| Operating Profit | 0.00 | -0.01 | -0.02 | 0.02 | 0.37 | 0.94 | 1.37 | 1.44 | 3.01 | -0.15 | -6.40 | -0.50 | -0.78 |
| OPM % | -3.17% | 0.45% | 2.01% | 4.28% | 4.94% | 5.51% | 4.86% | -0.20% | -38.51% | -9.52% | -10.34% | ||
| Other Income | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | 0.05 | 0.02 | 0.06 | 0.38 | 2.22 | -2.21 | 1.13 | 2.27 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 1.06 | 1.09 | 1.08 | 0.63 | 0.07 | 0.11 | 0.12 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.11 | 0.14 | 0.15 | 0.30 | 0.28 | 0.15 | 0.10 | 0.09 |
| Profit before tax | 0.00 | 0.00 | 0.01 | 0.04 | 0.27 | 0.87 | 0.19 | 0.26 | 2.01 | 1.16 | -8.83 | 0.42 | 1.28 |
| Tax % | 0.00% | 50.00% | 37.04% | 31.03% | 52.63% | 30.77% | 26.37% | 2.59% | 0.00% | -111.90% | |||
| Net Profit | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 0.60 | 0.09 | 0.18 | 1.49 | 1.13 | -8.83 | 0.88 | 1.72 |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 0.60 | 0.01 | 0.01 | 0.10 | 0.06 | -0.48 | 0.05 | 0.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 750.00% | 252.94% | -85.00% | 100.00% | 727.78% | -24.16% | -881.42% | 109.97% |
| Change in YoY Net Profit Growth (%) | 0.00% | 650.00% | -497.06% | -337.94% | 185.00% | 627.78% | -751.94% | -857.25% | 991.38% |
Vaxtex Cotfab Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -28% |
| 3 Years: | -56% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | -16% |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -17% |
| 3 Years: | -53% |
| 1 Year: | 49% |
| Return on Equity | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -5% |
| 3 Years: | -10% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:11 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 6.02 | 6.02 | 10.04 | 12.63 | 18.38 | 18.38 | 18.38 |
| Reserves | 3.53 | 3.53 | 3.53 | 3.55 | 3.72 | 4.33 | 2.63 | 2.85 | 0.32 | 10.85 | 0.42 | -0.04 | -1.06 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 3.29 | 12.62 | 10.30 | 7.45 | 5.20 | 11.51 | 11.13 | 10.92 |
| Other Liabilities | 0.03 | 0.00 | 0.27 | 0.75 | 5.82 | 5.49 | 6.65 | 2.52 | 6.18 | 40.80 | 18.56 | 19.00 | 17.46 |
| Total Liabilities | 3.96 | 3.93 | 4.20 | 4.70 | 10.19 | 13.51 | 27.92 | 21.69 | 23.99 | 69.48 | 48.87 | 48.47 | 45.70 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.36 | 1.70 | 1.80 | 2.37 | 3.85 | 3.90 | 3.65 | 1.14 | 1.04 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.89 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.08 | 1.05 | 1.10 | 7.01 | 7.54 | 5.27 |
| Other Assets | 3.07 | 3.88 | 4.20 | 4.34 | 8.49 | 11.71 | 25.43 | 17.76 | 19.04 | 64.73 | 40.72 | 39.89 | 40.42 |
| Total Assets | 3.96 | 3.93 | 4.20 | 4.70 | 10.19 | 13.51 | 27.92 | 21.69 | 23.99 | 69.48 | 48.87 | 48.47 | 45.70 |
Below is a detailed analysis of the balance sheet data for Vaxtex Cotfab Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.38 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.38 Cr..
- For Reserves, as of Sep 2025, the value is -1.06 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -0.04 Cr. (Mar 2025) to -1.06 Cr., marking a decline of 1.02 Cr..
- For Borrowings, as of Sep 2025, the value is 10.92 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 11.13 Cr. (Mar 2025) to 10.92 Cr., marking a decrease of 0.21 Cr..
- For Other Liabilities, as of Sep 2025, the value is 17.46 Cr.. The value appears to be improving (decreasing). It has decreased from 19.00 Cr. (Mar 2025) to 17.46 Cr., marking a decrease of 1.54 Cr..
- For Total Liabilities, as of Sep 2025, the value is 45.70 Cr.. The value appears to be improving (decreasing). It has decreased from 48.47 Cr. (Mar 2025) to 45.70 Cr., marking a decrease of 2.77 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 1.04 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 1.03 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 5.27 Cr.. The value appears to be declining and may need further review. It has decreased from 7.54 Cr. (Mar 2025) to 5.27 Cr., marking a decrease of 2.27 Cr..
- For Other Assets, as of Sep 2025, the value is 40.42 Cr.. The value appears strong and on an upward trend. It has increased from 39.89 Cr. (Mar 2025) to 40.42 Cr., marking an increase of 0.53 Cr..
- For Total Assets, as of Sep 2025, the value is 45.70 Cr.. The value appears to be declining and may need further review. It has decreased from 48.47 Cr. (Mar 2025) to 45.70 Cr., marking a decrease of 2.77 Cr..
However, the Borrowings (10.92 Cr.) are higher than the Reserves (-1.06 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -0.01 | -0.02 | 0.02 | 0.12 | -2.35 | -11.25 | -8.86 | -4.44 | -5.35 | -17.91 | -11.63 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 121.67 | 139.24 | 60.93 | 78.08 | 112.42 | 136.65 | 36.49 | 87.94 | 345.02 | 971.94 | ||
| Inventory Days | 64.04 | 35.35 | 35.24 | 15.72 | 70.56 | 28.50 | 36.53 | 6.96 | 3.50 | 0.00 | ||
| Days Payable | 160.09 | 53.91 | 133.87 | 127.24 | 104.80 | 36.50 | 35.52 | 152.60 | 293.74 | |||
| Cash Conversion Cycle | 25.61 | 120.68 | -37.69 | -33.44 | 78.17 | 128.65 | 37.51 | -57.70 | 54.78 | 971.94 | ||
| Working Capital Days | 28.97 | 290.02 | 45.30 | 15.78 | 88.09 | 211.04 | 68.04 | 116.08 | 458.56 | 1,177.04 | ||
| ROCE % | 0.00% | 0.00% | 0.25% | 1.02% | 6.49% | 14.21% | 8.54% | 6.68% | 16.71% | 2.02% | -20.72% | 1.77% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 2.00 | 10.00 |
| Basic EPS (Rs.) | 0.05 | -0.59 | 0.11 | 0.30 | 0.30 |
| Diluted EPS (Rs.) | 0.05 | -0.59 | 0.11 | 0.30 | 0.30 |
| Cash EPS (Rs.) | 0.05 | -0.47 | 0.11 | 0.35 | 0.54 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.99 | 1.02 | 1.86 | 2.06 | 14.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.99 | 1.02 | 1.86 | 2.06 | 14.73 |
| Revenue From Operations / Share (Rs.) | 0.28 | 0.90 | 5.99 | 12.33 | 43.42 |
| PBDIT / Share (Rs.) | 0.03 | -0.46 | 0.04 | 0.67 | 2.49 |
| PBIT / Share (Rs.) | 0.02 | -0.47 | 0.01 | 0.61 | 2.24 |
| PBT / Share (Rs.) | 0.02 | -0.48 | 0.09 | 0.40 | 0.43 |
| Net Profit / Share (Rs.) | 0.04 | -0.48 | 0.08 | 0.29 | 0.29 |
| PBDIT Margin (%) | 11.96 | -51.83 | 0.67 | 5.46 | 5.72 |
| PBIT Margin (%) | 9.97 | -52.75 | 0.30 | 4.98 | 5.15 |
| PBT Margin (%) | 7.83 | -53.15 | 1.53 | 3.24 | 1.00 |
| Net Profit Margin (%) | 16.81 | -53.15 | 1.49 | 2.39 | 0.68 |
| Return on Networth / Equity (%) | 4.81 | -47.01 | 4.82 | 14.34 | 2.00 |
| Return on Capital Employeed (%) | 2.03 | -30.18 | 0.80 | 18.53 | 7.04 |
| Return On Assets (%) | 1.82 | -18.07 | 1.62 | 6.19 | 0.82 |
| Long Term Debt / Equity (X) | 0.40 | 0.53 | 0.22 | 0.58 | 1.14 |
| Total Debt / Equity (X) | 0.60 | 0.61 | 0.22 | 0.71 | 1.16 |
| Asset Turnover Ratio (%) | 0.10 | 0.28 | 1.62 | 2.71 | 1.05 |
| Current Ratio (X) | 1.80 | 2.11 | 1.62 | 2.72 | 5.11 |
| Quick Ratio (X) | 1.80 | 2.10 | 1.59 | 1.99 | 4.44 |
| Inventory Turnover Ratio (X) | 48.96 | 21.35 | 19.63 | 16.24 | 7.54 |
| Interest Coverage Ratio (X) | 5.58 | -130.94 | 0.81 | 3.15 | 1.38 |
| Interest Coverage Ratio (Post Tax) (X) | 8.85 | -133.26 | 0.32 | 2.38 | 1.16 |
| Enterprise Value (Cr.) | 23.07 | 28.95 | 32.88 | 125.26 | 36.65 |
| EV / Net Operating Revenue (X) | 4.39 | 1.74 | 0.43 | 2.02 | 1.40 |
| EV / EBITDA (X) | 36.72 | -3.36 | 64.30 | 37.03 | 24.46 |
| MarketCap / Net Operating Revenue (X) | 2.27 | 1.05 | 0.36 | 1.91 | 1.01 |
| Price / BV (X) | 0.65 | 0.92 | 1.18 | 11.39 | 2.98 |
| Price / Net Operating Revenue (X) | 2.27 | 1.05 | 0.36 | 1.91 | 1.01 |
| EarningsYield | 0.07 | -0.50 | 0.04 | 0.01 | 0.01 |
After reviewing the key financial ratios for Vaxtex Cotfab Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.59 (Mar 24) to 0.05, marking an increase of 0.64.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.59 (Mar 24) to 0.05, marking an increase of 0.64.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has increased from -0.47 (Mar 24) to 0.05, marking an increase of 0.52.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.99. It has decreased from 1.02 (Mar 24) to 0.99, marking a decrease of 0.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.99. It has decreased from 1.02 (Mar 24) to 0.99, marking a decrease of 0.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.28. It has decreased from 0.90 (Mar 24) to 0.28, marking a decrease of 0.62.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has increased from -0.46 (Mar 24) to 0.03, marking an increase of 0.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from -0.47 (Mar 24) to 0.02, marking an increase of 0.49.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from -0.48 (Mar 24) to 0.02, marking an increase of 0.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 2. It has increased from -0.48 (Mar 24) to 0.04, marking an increase of 0.52.
- For PBDIT Margin (%), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from -51.83 (Mar 24) to 11.96, marking an increase of 63.79.
- For PBIT Margin (%), as of Mar 25, the value is 9.97. This value is below the healthy minimum of 10. It has increased from -52.75 (Mar 24) to 9.97, marking an increase of 62.72.
- For PBT Margin (%), as of Mar 25, the value is 7.83. This value is below the healthy minimum of 10. It has increased from -53.15 (Mar 24) to 7.83, marking an increase of 60.98.
- For Net Profit Margin (%), as of Mar 25, the value is 16.81. This value exceeds the healthy maximum of 10. It has increased from -53.15 (Mar 24) to 16.81, marking an increase of 69.96.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has increased from -47.01 (Mar 24) to 4.81, marking an increase of 51.82.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.03. This value is below the healthy minimum of 10. It has increased from -30.18 (Mar 24) to 2.03, marking an increase of 32.21.
- For Return On Assets (%), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 5. It has increased from -18.07 (Mar 24) to 1.82, marking an increase of 19.89.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.53 (Mar 24) to 0.40, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.61 (Mar 24) to 0.60, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.28 (Mar 24) to 0.10, marking a decrease of 0.18.
- For Current Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 2.11 (Mar 24) to 1.80, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.80, marking a decrease of 0.30.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 48.96. This value exceeds the healthy maximum of 8. It has increased from 21.35 (Mar 24) to 48.96, marking an increase of 27.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.58. This value is within the healthy range. It has increased from -130.94 (Mar 24) to 5.58, marking an increase of 136.52.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has increased from -133.26 (Mar 24) to 8.85, marking an increase of 142.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23.07. It has decreased from 28.95 (Mar 24) to 23.07, marking a decrease of 5.88.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.39. This value exceeds the healthy maximum of 3. It has increased from 1.74 (Mar 24) to 4.39, marking an increase of 2.65.
- For EV / EBITDA (X), as of Mar 25, the value is 36.72. This value exceeds the healthy maximum of 15. It has increased from -3.36 (Mar 24) to 36.72, marking an increase of 40.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 2.27, marking an increase of 1.22.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.65, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 2.27, marking an increase of 1.22.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from -0.50 (Mar 24) to 0.07, marking an increase of 0.57.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaxtex Cotfab Ltd:
- Net Profit Margin: 16.81%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.03% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.8
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.4 (Industry average Stock P/E: 451.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.81%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Textiles - General | J-03 (GF to 4th Floor) Tejendra Arcade, Nr, Ganjifarak Mill Compound, Ahmedabad Gujarat 380023 | vaxtexcotfab@gmail.com www.vaxtexcotfabltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aakash Rajeshbhai Thakor | Managing Director |
| Mr. Devi Singh | Non Executive Director |
| Mr. Pranav Vajani | Independent Director |
| Mr. Ravi Jitendra Modi | Independent Director |
| Mr. Harsh Mahendrakumar Kothari | Independent Director |
| Ms. Hardika Ladha | Independent Director |
FAQ
What is the intrinsic value of Vaxtex Cotfab Ltd?
Vaxtex Cotfab Ltd's intrinsic value (as of 15 December 2025) is 0.85 which is 61.19% lower the current market price of 2.19, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 40.2 Cr. market cap, FY2025-2026 high/low of 2.66/0.60, reserves of ₹-1.06 Cr, and liabilities of 45.70 Cr.
What is the Market Cap of Vaxtex Cotfab Ltd?
The Market Cap of Vaxtex Cotfab Ltd is 40.2 Cr..
What is the current Stock Price of Vaxtex Cotfab Ltd as on 15 December 2025?
The current stock price of Vaxtex Cotfab Ltd as on 15 December 2025 is 2.19.
What is the High / Low of Vaxtex Cotfab Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaxtex Cotfab Ltd stocks is 2.66/0.60.
What is the Stock P/E of Vaxtex Cotfab Ltd?
The Stock P/E of Vaxtex Cotfab Ltd is 23.4.
What is the Book Value of Vaxtex Cotfab Ltd?
The Book Value of Vaxtex Cotfab Ltd is 0.94.
What is the Dividend Yield of Vaxtex Cotfab Ltd?
The Dividend Yield of Vaxtex Cotfab Ltd is 0.00 %.
What is the ROCE of Vaxtex Cotfab Ltd?
The ROCE of Vaxtex Cotfab Ltd is 1.77 %.
What is the ROE of Vaxtex Cotfab Ltd?
The ROE of Vaxtex Cotfab Ltd is 4.74 %.
What is the Face Value of Vaxtex Cotfab Ltd?
The Face Value of Vaxtex Cotfab Ltd is 1.00.